Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832987 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRADAM17NFKB1THPO | |
| SCHEMBL283357 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRADAM17NFKB1THPO | |
| SCHEMBL713247 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRADAM17NFKB1THPO | |
| SCHEMBL11339365 | 0.88 | TSHR (0.56) | ALDH1A1TSHRADAM17NFKB1TP53 | |
| SCHEMBL16356392 | 0.88 | ADAM17 (0.33) | ALDH1A1TSHRADAM17 | |
| SCHEMBL18902855 | 0.86 | ADAM17 (0.33) | ALDH1A1TSHRADAM17 | |
| SCHEMBL7259228 | 0.86 | ADAM17 (0.33) | ALDH1A1TSHRADAM17 | |
| SCHEMBL21631865 | 0.84 | ALDH1A1 (0.33) | ALDH1A1TSHRADAM17NFKB1THPO | |
| SCHEMBL8284890 | 0.84 | ALDH1A1 (0.33) | ALDH1A1TSHRADAM17NFKB1THPO | |
| SCHEMBL12000465 | 0.84 | ALDH1A1 (0.33) | ALDH1A1TSHRADAM17NFKB1THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108948-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2049472-B1 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBVIE BAHAMAS LTD (BS) | 2015-01-21 | — | — | EP | disclosed |
| US-8829041-B2 | Cyclopropyl amine derivatives | ABBVIE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| CN-101952267-A | Cyclopropylamine Derivatives | ABBOTT LAB | 2011-01-19 | — | — | CN | disclosed |
| EP-2231631-A1 | CYCLOPROPYL AMINE DERIVATIVES | Abbott Laboratories (US) | 2010-09-29 | — | — | EP | disclosed |
| CN-101472887-A | Cyclopropylamine derivatives as modulators of the histamine H3 receptor | ABBOTT LAB (US) | 2009-07-01 | — | — | CN | disclosed |
| WO-2009079225-A1 | CYCLOPROPYL AMINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | WO | disclosed |
| EP-2049472-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | Abbott Laboratories (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080242653-A1 | Cyclopropyl amine derivatives | ABBVIE INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | ABBVIE INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007150010-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-0433188-A1 | Possibly thermotropic polymolecular associations based on hydrogen bonded monomers, process for their preparation and monomers for carrying out this process | RHONE-POULENC CHIMIE (FR) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | HRH4, HRH3, HNMT | ALDH1A1 852/4885TSHR 1156/4885ADAM17 2345/4885 |
| US-20080242653-A1 | Cyclopropyl amine derivatives | HRH3, HRH4, HRH2 | ALDH1A1 1397/4885TSHR 139/4885ADAM17 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.